BAVENCIO® (avelumab) is indicated for the maintenance treatment of patients with locally advanced or metastatic urothelial carcinoma (UC) that has not progressed with first-line platinum-containing chemotherapy.

The FIRST and ONLY immunotherapy approved in the first-line maintenance setting


National Comprehensive Cancer Network® (NCCN®) Recommendation

Avelumab (BAVENCIO) maintenance is the only NCCN CATEGORY 1 and PREFERRED immunotherapy option for both cisplatin-eligible and -ineligible patients with locally advanced or metastatic UC that has not progressed on first-line platinum-containing chemotherapy.1

Category 1=Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.
Preferred intervention=interventions that are based on superior efficacy, safety, and evidence; and, when appropriate, affordability. 

Reference: 1. Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Bladder Cancer V.4.2021. © National Comprehensive Cancer Network, Inc. 2021. NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way. All rights reserved. Accessed September 2, 2021. To view the most recent and complete version of the guideline, go online to